Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
Andrew Jallouk, Sushanth Gouni, Jason R. Westin, Lei Feng, Haleigh Mistry, Raphaël Steiner, J Garnsey James, Mansoor Noorani, Sandra Horowitz, Nahum Puebla‐Osorio, Luis Fayad, Swaminathan P. Iyer, Misha Hawkins, Christopher R. Flowers, Sairah Ahmed, Loretta J. Nastoupil, Partow Kebriaei, Elizabeth J. Shpall, Sattva S. Neelapu, Yago Nieto, Paolo Strati
Abstract
SD/PD (N=142) PR (N=41) CMR (N=13) P value CMR vs. SD/PD P value CMR vs. PR DLBCL/HGBCL, N (%) 105 (74) 29 (71) 10 (77) 0.814 0.664 Age in years, median (range) 59 (21-85) 61 (18-78) 53 (39-72) 0.446 0.485 Male, N (%) 92 (65) 29 (71) 7 (54) 0.432 0.260 ECOG 2-4, N (%) 22 (16) 7 (17) 1 (8) 0.449 0.407 CRP mg/L, median (range) 21.9 (0.3-283.7) 7.1 (0.3-246.2) 7.7 (1.8-29.1) 0.023 0.879 Ferritin mg/L, median (range) 810.5 (13-38,964) 679 (69-3,834) 602 (101-3,190) 0.640 0.671 Previous therapies >2, N (%) 115 (81) 35 (85) 8 (62) 0.097 0.063 Bridging therapy use, N (%) 63 (44) 28 (68) 6 (46) 0.901 0.150 Bridging chemotherapy, N (%) 43 (30) 22 (54) 4 (31) 0.971 0.150 Disease refractory to prior therapy, N (%) 113 (80) 31 (76) 6 (46) 0.006 0.046 Previous autologous SCT, N (%) 34 (24) 5 (12) 4 (31) 0.584 0.117 Previous allogeneic SCT, N (%) 4 (3) 0 (0) 0 (0) 0.